1. Home
  2. REPL vs SLP Comparison

REPL vs SLP Comparison

Compare REPL & SLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

HOLD

Current Price

$9.71

Market Cap

407.1M

Sector

Health Care

ML Signal

HOLD

Logo Simulations Plus Inc.

SLP

Simulations Plus Inc.

HOLD

Current Price

$18.25

Market Cap

367.9M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
REPL
SLP
Founded
2015
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
407.1M
367.9M
IPO Year
2018
1996

Fundamental Metrics

Financial Performance
Metric
REPL
SLP
Price
$9.71
$18.25
Analyst Decision
Hold
Buy
Analyst Count
9
6
Target Price
$5.67
$24.00
AVG Volume (30 Days)
3.2M
692.5K
Earning Date
05-21-2026
04-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.43
Revenue
N/A
$59,577,000.00
Revenue This Year
N/A
$3.80
Revenue Next Year
N/A
$5.90
P/E Ratio
N/A
$42.41
Revenue Growth
N/A
10.52
52 Week Low
$1.50
$11.09
52 Week High
$13.24
$21.01

Technical Indicators

Market Signals
Indicator
REPL
SLP
Relative Strength Index (RSI) 47.68 63.10
Support Level $9.69 $17.74
Resistance Level $10.71 $18.62
Average True Range (ATR) 0.74 0.15
MACD -0.38 -0.12
Stochastic Oscillator 22.42 15.38

Price Performance

Historical Comparison
REPL
SLP

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

About SLP Simulations Plus Inc.

Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.

Share on Social Networks: